Josh Shin
PARTNER AT FANGDA PARTNERS Mr. Josh Shin has over 18 years of experience in M&A, private equity investment, regulatory advisory and general corporate works, with extensive knowledge in the industries of life science and healthcare. He was graduated from University College London and Fudan University, and was admitted in the PRC. Mr. Shin maintains a balanced practice focus on transactional and regulatory advisory matters. He has deep insights in representing clients in all types of life sciences practice and now leads the healthcare practice of the firm’s corporate group. He is considered as one of the most active Chinese lawyers …
PARTNER AT FANGDA PARTNERS
Mr. Josh Shin has over 18 years of experience in M&A, private equity investment, regulatory advisory and general corporate works, with extensive knowledge in the industries of life science and healthcare. He was graduated from University College London and Fudan University, and was admitted in the PRC.
Mr. Shin maintains a balanced practice focus on transactional and regulatory advisory matters. He has deep insights in representing clients in all types of life sciences practice and now leads the healthcare practice of the firm’s corporate group. He is considered as one of the most active Chinese lawyers in various product/compound related collaboration transactions, including license-in and license-out, commercialization, exclusive promotion and customized collaboration arrangements. In addition, Mr. Shin has a proven track record in advising clients on regulatory-related issues covering a variety of cutting-edge legal issues. His clients include companies in the areas of pharmaceuticals, biotechnology, medical devices, in vitro diagnostics, R&D services, and innovative pharmaceutical service platforms.
He was mentioned as leading lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 through 2021, Chambers and Partners – Greater China in 2022, as leading individual for life sciences by Legal 500 2020 – 2023, and as distinguished practitioner in Healthcare legal services by Asia Law 2022.
See more
Mr. Josh Shin has over 18 years of experience in M&A, private equity investment, regulatory advisory and general corporate works, with extensive knowledge in the industries of life science and healthcare. He was graduated from University College London and Fudan University, and was admitted in the PRC.
Mr. Shin maintains a balanced practice focus on transactional and regulatory advisory matters. He has deep insights in representing clients in all types of life sciences practice and now leads the healthcare practice of the firm’s corporate group. He is considered as one of the most active Chinese lawyers in various product/compound related collaboration transactions, including license-in and license-out, commercialization, exclusive promotion and customized collaboration arrangements. In addition, Mr. Shin has a proven track record in advising clients on regulatory-related issues covering a variety of cutting-edge legal issues. His clients include companies in the areas of pharmaceuticals, biotechnology, medical devices, in vitro diagnostics, R&D services, and innovative pharmaceutical service platforms.
He was mentioned as leading lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 through 2021, Chambers and Partners – Greater China in 2022, as leading individual for life sciences by Legal 500 2020 – 2023, and as distinguished practitioner in Healthcare legal services by Asia Law 2022.
